Abdulrahman Katib on RENOVE’s Support of Practice in VTE Longterm Managment
Abdulrahman Katib, Internal Medicine and Adult Thrombosis Consultant at King Faisal Specialist Hospital and Research Center, shared on LinkedIn:
”RENOVE is an important RCT that supported our practice in VTE longterm managment.
It was a high-quality multicenter randomized clinical trial that provided strong real-world evidence on extended anticoagulation after VTE.
It showed that long-term dosing decisions should focus not only on preventing recurrence, but also on reducing bleeding risk, which directly improved how we individualize therapy in practice.
Since RENOVE, our approach became more patient-centered, with more confident use of reduced-dose DOAC strategies in selected patients needing extended anticoagulation.”
Read the full article here.
Article: Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial
Authors: Francis Couturaud et al. for the RENOVE Investigators
Stay updated on all scientific advances with Hemostasis Today.
-
Jan 17, 2026, 14:30Jecko Thachil Shares a Perspective on von Willebrand Disease
-
Jan 17, 2026, 14:16Fadi Alshrouf Explains Red Blood Cell Exchange
-
Jan 17, 2026, 13:42David McIntosh Shares a Sequel for Blood and Plasma Donors
-
Jan 17, 2026, 12:36Tomasz Brzoska on The Role of Circulating TF in Pulmonary Arterial Thrombosis
-
Jan 17, 2026, 12:25Ahmed Nasreldein Honored to Moderate Scientific Session at ASO’s Webinar on Stroke Imaging
-
Jan 17, 2026, 12:16Michael Makris on UK’s National Self-Assesment Questionnaire on VTE
-
Jan 17, 2026, 11:58Grigoris Gerotziafas Shares The APICAT Study Post Hoc Analysis
-
Jan 17, 2026, 11:45Emmanuel J Favaloro Shares Yet Another Paper from The 100th Anniversary of VWD
-
Jan 17, 2026, 05:05Dr Abdul Mannan: Iron Deficiency Can Hide Beta-Thalassaemia Trait